What is Idhifa used to treat?

Key Points

• Idhifa (enasidenib) is an oral medication used to treat adult patients with acute myeloid leukemia (AML), a type of cancer of the blood and bone marrow. It is used if you have a specific genetic mutation known as IDH2 (isocitrate dehydrogenase-2).
• Idhifa is used in patients with AML that has returned after initial treatment (relapsed) or has not responded to treatment (refractory).
• It is not known if Idhifa is safe or effective in children.

Idhifa is approved to be used with the RealTime IDH2 Assay, a diagnostic that detects specific mutations in the IDH2 gene in patients with AML. IDH2 gene mutations may lead to immature blood cells becoming cancerous and dividing uncontrollably, causing AML.

How do I take Idhifa?

Take Idhifa exactly as your doctor orders. The recommended dose of Idhifa is 100 mg orally once daily. You can take your medicine with or without food. Take your dose at about the same time each day. Do not split or crush your tablets.

If you vomit after taking your medicine, you miss a dose, or you miss the usual time you take your medicine, take the dose as soon as possible on the same day, and return to the normal schedule the following day.

You will take Idhifa until your disease worsens or you have unacceptable side effects to the treatment. Your dose may need to be modified or treatment interrupted if you have certain side effects. In general, treatment will be continued for at least 6 months if possible.

Idhifa comes as 50 mg tablet and 100 mg oral tablet and is manufactured by Celgene.

This is not all the information you need to know about Idhifa (enasidenib) for safe and effective use. Review the full Idhifa information here, and discuss this information with your doctor or other health care provider.